We are honored to have been selected amongst the finalists for the Boehringer Ingelheim Innovation Day and looking forward to presenting Remedium Bio and our Prometheus™ dose-adjustable gene therapy platform technology on Oct 26th.

#genetherapy #biotechnology #innovation


Remedium selected as finalist for

Boehringer Ingelheim

Innovation Day

BOSTON, Oct 16, 2023 – Remedium Bio is excited to announce that the company has been selected as a finalist for the in-person pitch competition at the upcoming Boehringer Ingelheim (BI) External Innovation Day.

This year’s BI Innovation Day will take place on Oct 26th at the Boehringer Ingelheim Biopharmaceuticals Business Unit headquarters at Fremont, California.

Remedium will present its Prometheus™ dose adjustable gene therapy platform technology – a first-in-class system, which enables ultra-low-cost delivery of virtually any subcutaneously administered biologic, as a single injection adjustable dose gene therapy.

The company will also highlight progress on its pipeline candidate for the treatment of Type 2 Diabetes and Obesity RMD1202 – a single injection, adjustable dose, subcutaneously administered GLP-1 Receptor Agonist gene therapy.

“We are very honored to have been selected amongst the finalists for this highly competitive and prestigious event” said Frank Luppino, President and CEO of Remedium.

“We look forward to presenting our novel platform and in vivo efficacy results for its first indication in a translatable model of Type 2 Diabetes and Obesity”.

#genetherapy #biotechnology #venturecapital


Boehringer Ingelheim Innovation Prize | Boehringer Ingelheim

Profile photo of Luppino, FrankRemedium Bio is a gene therapy company focused on the development of treatments for large unmet clinical needs.

To enable this, we developed a revolutionary gene therapy platform technology, which enables safe, effective, and durable delivery of therapeutic genes while allowing for simple post-treatment dose adjustment.

The Prometheus™ adjustable gene therapy platform is able to safely and durably replace multi-injection subcutaneously administered biologics, with a single treatment, at a fraction of the cost, and without genetic integration.

Our lead product is a disease-modifying treatment for Osteoarthritis that is based on the only clinically validated chondro-regenerative mechanism.

Remedium’s pipeline includes gene therapy treatments in the fields of Weight Loss, Type 2 Diabetes, and Stroke.

Remedium has developed the only dose-adjustable gene therapy platform: Prometheus™.

The technology utilizes a highly biocompatible, non-viral delivery vector, for targeted, durable, and adjustable gene expression.

Prometheus™ enables replacement of virtually any subcutaneously administered protein as a single injection, adjustable dose gene therapy – at a fraction of the current treatment cost and with improved pharmacokinetics.